- Home
- GLQ vs ENTA Comparison
GLQ vs ENTA Comparison
Compare GLQ & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLQ
- ENTA
- Stock Information
- Founded
- GLQ 2005
- ENTA 1995
- Country
- GLQ United States
- ENTA United States
- Employees
- GLQ N/A
- ENTA N/A
- Industry
- GLQ Finance/Investors Services
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- GLQ Finance
- ENTA Health Care
- Exchange
- GLQ Nasdaq
- ENTA Nasdaq
- Market Cap
- GLQ 119.5M
- ENTA 112.4M
- IPO Year
- GLQ N/A
- ENTA 2013
- Fundamental
- Price
- GLQ $6.83
- ENTA $6.29
- Analyst Decision
- GLQ
- ENTA Buy
- Analyst Count
- GLQ 0
- ENTA 4
- Target Price
- GLQ N/A
- ENTA $17.25
- AVG Volume (30 Days)
- GLQ 65.5K
- ENTA 119.2K
- Earning Date
- GLQ 01-01-0001
- ENTA 05-12-2025
- Dividend Yield
- GLQ 11.11%
- ENTA N/A
- EPS Growth
- GLQ N/A
- ENTA N/A
- EPS
- GLQ N/A
- ENTA N/A
- Revenue
- GLQ N/A
- ENTA $64,462,999.00
- Revenue This Year
- GLQ N/A
- ENTA N/A
- Revenue Next Year
- GLQ N/A
- ENTA N/A
- P/E Ratio
- GLQ N/A
- ENTA N/A
- Revenue Growth
- GLQ N/A
- ENTA N/A
- 52 Week Low
- GLQ $5.13
- ENTA $4.09
- 52 Week High
- GLQ $6.54
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- GLQ 67.76
- ENTA 61.49
- Support Level
- GLQ $6.67
- ENTA $5.55
- Resistance Level
- GLQ $6.77
- ENTA $6.23
- Average True Range (ATR)
- GLQ 0.09
- ENTA 0.33
- MACD
- GLQ -0.00
- ENTA 0.06
- Stochastic Oscillator
- GLQ 100.00
- ENTA 94.74
About GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.